MS8588
MS8588 is a deubiquitinase-targeting chimera (DUBTAC) against cGAS. MS8588 induces targeted stabilization of cGAS, thereby activating downstream signaling pathways. MS8588 activates the cGAS/STING/IRF3 innate immune signaling pathway. MS8588 exhibits antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 3060519-94-7
- Formula: C45H59Cl2N9O6S
- Molecular Weight:924.98
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
MS8588 (0-10 μM; 0-24 h) stabilizes cGAS and activates the cGAS/STING/IRF3 signaling pathway in HeLa cells in a concentration-, time-, cGAS- and OTUB1-dependent manner, without altering the expression level of cGAS mRNA; its stabilizing effect on cGAS reaches a peak when acting at 5 μM for 24 h[1].
MS8588 (5 μM; 2-14 days) effectively inhibits the proliferation and colony-forming ability of HeLa cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa cells
-
Concentration:5 μM
-
Incubation Time:2 days (proliferation assay); 2 weeks (clonogenicity assay)
-
Result:Significantly suppressed cell proliferation compared to vehicle control at 5 μM for 2 days.
Drastically reduced cell colony formation at 5 μM for 2 weeks.
Chemical Information
-
CAS No. 3060519-94-7
-
Molecular Weight 924.98
-
Formula C45H59Cl2N9O6S
-
SMILES
ClC1=C(NC2=C3CN(C(CO)=O)CC2)C3=C(C4=NN(CCNC(CCCCCCCCCC(NCCC5=CC=C(N6C(CN(C(/C=C/CN(C)C)=O)CC6)=O)S5)=O)=O)C=C4)C=C1Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MS8588 Related Classifications
HY-162967 Related Classifications
Powered by Bioz